Ammonia (urease) production

Your liver converts ammonia into urea, which your kidneys can excrete. Some urea enters the digestive tract, where microbes break it down again using urease. Older human tracer studies estimated that microbes break down about 15% to 30% of the urea produced in healthy adults. Some of that nitrogen supports microbial growth, and some returns to the circulation.

This stool marker estimates your gut community's capacity to produce ammonia through that reaction. It's a research-stage measurement. Its ability to predict illness, guide treatment or improve preventive care hasn't been established.

What the Result Reflects

The lab sequences microbial DNA in your stool. This is called metagenomic sequencing. The ammonia (urease) production result uses this information to estimate the relative abundance of microbes with the genetic capacity to break down urea. The percentage describes predicted microbial capacity, rather than a concentration of ammonia or a direct measurement of enzyme activity.

Actual ammonia production depends on whether those genes are active, how much urea is available and conditions inside the bowel. Microbes can also use ammonia to build their own proteins. The amount that eventually reaches your blood therefore depends on several processes beyond the presence of urease genes.

Bacterial urease is one source of intestinal ammonia. Bacteria also release ammonia when they break down amino acids, and cells lining the small intestine produce ammonia during their own metabolism. Human studies don't support assigning a fixed share of all intestinal ammonia production to the urease capacity measured in stool.

Liver Disease and Ammonia

Hepatic encephalopathy is a disorder of brain function caused by liver failure or blood bypassing the liver. Ammonia contributes to it, alongside factors such as inflammation. Symptoms can include slowed thinking, confusion and severe drowsiness, and advanced episodes can progress to coma.

In one human study, people with decompensated cirrhosis had more stool DNA for urease from Streptococcus salivarius. Decompensated cirrhosis is liver scarring that has begun causing complications. The study measured a particular bacterium's urease genes, so its findings don't establish how this whole-community percentage predicts your risk.

The stronger outcome evidence concerns blood ammonia. A study of 754 stable outpatients with cirrhosis found that higher plasma ammonia predicted later hospitalization for liver complications and death after adjustment for other indicators of disease severity. A separate study of 549 people with advanced chronic liver disease also linked higher blood ammonia to subsequent complications. Neither study measured this stool result, so their risk estimates cannot be applied to it.

Mouse and cell-culture experiments also suggest that ammonia can contribute to alcohol-related fat accumulation in the liver. Those experiments provide a possible mechanism, but they don't establish this stool marker as a predictor of alcohol-related liver disease in people.

Kidney Disease

When kidney function declines, urea can accumulate in the blood and become more available to gut microbes. A study comparing people with end-stage kidney disease with healthy controls found more bacterial families known to contain urease-producing members, together with fewer families capable of producing butyrate. The researchers inferred these functions from bacterial family profiles and reference information; they didn't directly measure this stool percentage or ammonia production.

Experiments with cultured human intestinal cells found that urea damaged the barrier between cells and that adding urease made the damage worse. This supports a possible mechanism linking retained urea with intestinal barrier problems in kidney disease. It doesn't establish that an individual stool result measures barrier damage or predicts declining kidney function.

Why a Low Result Isn't Automatically Better

Sarcopenia involves loss of muscle mass and strength. In a study of 152 adults, predicted urease gene abundance was lower in women with sarcopenia and in participants who had both cirrhosis and sarcopenia. The study sequenced a bacterial identification gene and inferred functional genes from the bacterial profile, a different approach from this test's broader DNA analysis.

That study didn't measure blood ammonia or establish that increasing urease protects muscle. Urease allows microbes to reuse nitrogen, but the benefit to your body depends on what happens to that nitrogen afterward. A low stool percentage doesn't diagnose inadequate protein intake, and a higher percentage hasn't been established as a way to preserve muscle.

When Results Can Be Misleading

• Genetic capacity versus activity: DNA can identify the capacity for a reaction without showing how much of that reaction is happening.
• Relative percentages: the proportion of urease-capable microbes can rise because other microbes become less abundant, even without an increase in the absolute number of urease-capable organisms.
• Medication use: an observational study associated proton pump inhibitors and beta-blockers with higher predicted urease gene abundance. It used a different sequencing analysis and couldn't establish that the medicines caused the difference.
• Recent antibiotics, bowel preparation or changed bowel habits: these can alter the sampled microbial community. Their effect on this particular percentage cannot be assumed to follow a consistent direction.
• Collection and analysis: sample handling, DNA extraction, reference databases and computational methods can affect the result. Percentages from different laboratories or analytical methods aren't directly interchangeable.

What Serial Results Can Show

Repeated samples can document changes in your microbial profile. A change in this percentage hasn't been validated as evidence of improved ammonia clearance, reduced liver risk or successful treatment. A trend needs the same caution as a single result.